Loading
Muscle Physiology and Disorders · Journal article
Frontiers in Oncology · August 14, 2026
Encouraging direction, but not yet definitive.
This retrospective study of 381 advanced NSCLC patients identifies three distinct treatment-associated physiological phenotypes (Stable, Wasting, Collapse) based on early changes in muscle mass and physical function. Combination therapy is associated with greater physiological deterioration and transition to vulnerable phenotypes, with the Collapse phenotype showing median overall survival of 18.0 months versus OS not reached in the Stable phenotype. While physiological phenotyping improves survival discrimination beyond conventional tumor response assessment, the findings are exploratory and require prospective validation.
Retrospective cohort study with inverse probability of treatment weighting and unsupervised clustering analysis. Patients with advanced non-small cell lung cancer receiving penpulimab monotherapy (n=153) or combination therapy (n=228) between September 2021 and March 2023.. Intervention: Penpulimab monotherapy or combination therapy with assessment of skeletal muscle index, muscle attenuation, and functional measures at baseline and 12 weeks. Compared with: Monotherapy versus combination therapy groups; Stable versus Wasting versus Collapse physiological phenotypes. n = 381.
Combination therapy associated with greater early physiological deterioration including larger declines in muscle mass and physical performance compared to monotherapy Three distinct physiological phenotypes identified: Stable (P1), Wasting (P2), and Collapse (P3) with different survival patterns Collapse phenotype exhibited poorest overall survival with median OS of 18.0 months, whereas OS was not reached in Stable phenotype
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider early physiological profiling (muscle mass and functional decline) as a complementary risk stratification tool in advanced NSCLC beyond tumor response assessment. Patients on combination therapy appear at higher risk for early muscle and functional decline; however, prospective validation is needed before implementing phenotype-directed interventions.
Retrospective analysis with sound methodology (IPTW-adjusted, unsupervised clustering) identifying reproducible physiological phenotypes associated with survival outcomes in advanced NSCLC, but requiring prospective validation and lacking pre-specified primary endpoints.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider early physiological profiling (muscle mass and functional decline) as a complementary risk stratification tool in advanced NSCLC beyond tumor response assessment. Patients on combination therapy appear at higher risk for early muscle and functional decline; however, prospective validation is needed before implementing phenotype-directed interventions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective To characterize early changes in skeletal muscle and physical function among patients with advanced non-small cell lung cancer (NSCLC) receiving penpulimab monotherapy or combination therapy, and to identify distinct treatment-associated physiological phenotypes with potential clinical relevance. Methods We retrospectively analyzed 381 patients with advanced NSCLC (monotherapy, n = 153; combination therapy, n = 228) treated between September 2021 and March 2023. Inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics between treatment groups. Skeletal muscle index (SMI), muscle attenuation, and functional measures were assessed at baseline and 12 weeks. Unsupervised clustering was performed to identify early physiological phenotypes based on longitudinal changes in muscle and functional parameters. Exploratory survival analyses were conducted using 12-week landmark models to evaluate the association between physiological phenotypes and overall survival (OS). Results After IPTW adjustment, combination therapy was associated with greater early physiological deterioration, including larger declines in muscle mass and physical performance, increased incidence of new-onset sarcopenia, and poorer treatment tolerability compared with monotherapy. Unsupervised clustering identified three distinct physiological phenotypes: Stable (P1), Wasting (P2), and Collapse (P3). Combination therapy was associated with a higher likelihood of transition to vulnerable phenotypes, particularly P2 and P3. These phenotypes demonstrated distinct clinical characteristics and survival patterns, with the Collapse phenotype exhibiting the poorest OS (median OS, 18.0 months), whereas OS was not reached in the Stable phenotype. Incorporation of physiological phenotypes improved the discrimination of landmark survival models beyond baseline clinical characteristics and radiographic response assessments. Exploratory pathway analyses suggested potential associations between early physiological deterioration patterns and survival differences; however, these findings require prospective validation. Conclusions Early treatment-associated physiological deterioration in advanced NSCLC is heterogeneous and can be characterized by reproducible dynamic phenotypes. Combination therapy is associated with greater early declines in muscle and physical function, while longitudinal physiological phenotyping provides complementary information for identifying patients at increased risk of adverse outcomes beyond conventional tumor response assessment. Prospective studies are warranted to validate these findings and determine whether interventions targeting physiological decline can improve clinical outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.